Vraylar (cariprazine) is a prescription drug used to treat certain mental health conditions, such as bipolar disorder. Vraylar comes as a capsule that you swallow. Vraylar is a prescription drug ...

The active ingredient in Vraylar is cariprazine. It belongs to a group of drugs called atypical antipsychotics. These drugs regulate your levels of the neurotransmitters serotonin and dopamine.

It also includes data from a long-term, open-label study that focused on the safety and tolerability of the drug over 26 weeks. Vraylar is now one of AbbVie's fastest-growing products with sales ...

Cariprazine (Vraylar), a treatment for bipolar disorder, may also be an off-label option. These medications work by affecting receptors (called neurotransmitters) for chemicals in the brain that ...

The new indication is a lynchpin of AbbVie's plan to grow Vraylar into a $4 billion product, a sizeable increase from the $1.7 billion it achieved last year. After a slow start, the drug has ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

or Vraylar) or to help prevent relapses during long-term use (e.g., Abilify, Geodon, Seroquel, and Zyprexa). In addition, the doctor may prescribe an antidepressant, an anti-anxiety medication ...

Richter's Cariprazine, an antipsychotic developed in the early 2000s, is approved by the U.S. Food and Drug Administration and sold as Vraylar in the United States by AbbVie (ABBV.N), opens new tab.